Summary
Oxford Nanopore Technologies published its scheduled H1 2026 trading update, reporting first-half revenue of approximately 6.5 million, representing 10% growth on a reported basis and 12% at constant currency. The figure was below management expectations and was followed by a sharp share-price decline.
Market reaction
Shares of the company fell 20.5% to 96.2p on the trading update. Intraday trading took the stock to a 52-week low of 95.7p. The decline came even as broader U.S. equity indices moved higher - the S&P 500 gained 0.4% and the Nasdaq rose 0.3% - suggesting the sell-off was driven by company-specific factors rather than a wider market or sector downturn.
What drove the revenue shortfall
Management attributed the H1 revenue miss largely to geographic headwinds. Revenue in China fell by 16%, a contraction the company linked to tightened export control restrictions that have substantially limited its ability to operate in one of its historically significant markets. The Middle East also weighed on results, with revenue down by approximately 14% amid ongoing geopolitical disruption.
Implications for full-year guidance
Oxford Nanopore had set a 2026 full-year revenue growth target in the range of 21-25%. With reported first-half growth of only 10%, investors are questioning whether the second half of the year can deliver the acceleration needed to meet that guidance. The gap between the half-year outcome and the full-year target has increased perceived execution risk, prompting investors to reprice the stock.
Financial profile amplifies risk
The company remains loss-making and is targeting EBITDA breakeven in 2027. That trajectory leaves limited tolerance for underperformance on the top line, and the lower-than-expected H1 revenue print magnifies concerns over cash-flow generation and the timeline to profitability.
Competitive and sector context
Other players in genomic sequencing, including Illumina and Pacific BioSciences, face similar China-related challenges impacting access to that market. Nonetheless, the immediate share-price move appears to stem from Oxford Nanopore -specific disclosure rather than a sector-wide event.
Near-term outlook and timing
Investors will have to wait for the full half-year results due on 19 August 2026 for a more detailed account of performance drivers and management s view on whether full-year targets remain achievable. Until then, the company faces an extended period of uncertainty that is likely to keep execution risk elevated in investors positions.
Key statistics reiterated
- H1 revenue: approximately 6.5 million
- Reported H1 growth: 10% (12% at constant currency)
- China revenue decline: 16%
- Middle East revenue decline: approximately 14%
- Full-year 2026 revenue guidance: 21-25% growth
- EBITDA breakeven targeted in 2027
- Full half-year results due: 19 August 2026
For investors and market participants, the immediate challenge is assessing whether the company can materially accelerate growth in the back half of 2026 to close the gap to its guidance, given the geographic constraints identified in this update.